Sitemap

Posts

• Newcells Biotech joins StemBANCC consortium
• ARVO Highlights
• Latest innovation in retina models brings a fully characterised Retina Pigment Epithelium (RPE)
• Antibody drug conjugates (ADCs) – the role of in vitro models in safety assessment
• The inside story of the development of Newcells’ MPS flow model: Scientific chat with Dr Colin Brown
• Newcells Biotech collaborates with consortium in Eurostars funded project to advance novel therapy for Alpha-1 Antitrypsin (AAT) Deficiency
• The latest FMT Assay: An invaluable tool for modelling fibrotic disease
• New Product Launched – aProximate™ 96-well Assay-Ready Plates
• NB staff supports Motor Neurone Disease Charity
• Newcells team support charity with festive jumpers
• NB completes a licensing agreement with ID Pharma Co. Ltd for induced pluripotent stem cell technologies
• NB to develop a new skin metabolism model using iPSC derived skin cells
• Development of iPSC-derived conducting airways & application to toxicity testing
• 3rd ILD Summit Highlights
• Renal drug handling and drug-drug interactions in ADMET
• hiPSCs derived cells in disease modelling
• Current cell-based screens are poor models of human biology
• NB to develop 3D retinal organoids using hiPSC derived skin cells
• British Toxicological Society Annual Congress 2018 – Hilton Gateshead (16th-18th April)
• Dr Chichagova awarded best In Vitro Toxicology Society poster
• FMS Post-Doc Symposium 2018 – Newcastle University (15th June 2018)
• 17th Annual World Preclinical Congress – Boston, MA (18th-21st June)
• Review article – Cellular regeneration strategies for macular degeneration: past, present & future
• How the NHS Changed Our World: Tyneside’s Genetic Pioneers on BBC 1 (North East & Cumbria)
• NB secures £2M investment from NVM Private Equity & Northstar Ventures to accelerate hiPSC growth
• Press Release: Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes
• ASGCT 2025: Transforming Gene and Cell Therapy
• ARVO 2025: Complexity, Confidence, and the Case for In Vitro
• Announcement: New scientific publication in collaboration with the University of Newcastle
• Celebrating talented female scientists at Newcells Biotech
• Press Release: Newcells Biotech raises additional funding from investors
• How is AI Impacting drug discovery?
• Transforming Drug Development with 3D Retina Models
• Ask an expert: What are the latest trends in in vitro models?
• Scientific discussion with our CSO: what is next for in vitro models?
• Newcells Biotech launches Lung Ciliary Beat Frequency assay to enhance safety and efficacy profiling in preclinical drug development
• The Intensity of Innovation: Insights from the Japanese Society of Toxicology Conference
• Latest advances in In Vitro models
• 22nd North American ISSX Meeting – Montréal, Canada (15th-19th July)
• Newsletter June 2024
• Newcells Biotech strengthens executive and US team with key appointments
• Press Release : Newcells Biotech strengthens executive and US team with key appointments
• Biotech firm raises £2.3m for lab models that help avoid animal testing
• Dr Emanuela Costigliola joins Newcells Biotech’s executive team as a Chief Marketing Officer
• Overcoming optimisation hurdles of high-throughput FMT assay
• An insight into R&D at Newcells Biotech with Dr Fiona Leslie, PhD, Lung platform scientist
• Mr Terry Pizzie joins Newcells Biotech Board as non-executive director
• Imaging propels our kidney assays to the next level
• Latest Advances in CAR-T Therapy with novel HLA-typed in vitro cell tools
• MPS summit highlights
• Lung epithelium in vitro modelling of SARS-CoV2 infections to aid Covid-19 treatments
• Newcells scales up its operations in The Biosphere
• Development of functioning in vitro lung assay for modelling Covid-19 infection
• Diagnosing unresolved Stargardt disease using retina-specific splicing isoforms obtained from retinal organoids
• Development of a physiologically relevant lung model for understanding SARS-CoV-2 infection
• Improved in vitro renal tubular drug transport modelling to meet regulatory & development cost challenges
• Covid-19 action plan – 2021 update
• Developing a 3D in vitro proximal tubule model for chronic toxicity studies
• Newcells Biotech secures over £5m for 3D tissue models
• Our commitment to the 3Rs
• Successful EU initiative adds a new 3D lung airway model to NB’s portfolio for drug safety testing
• NB collaborates with Takeda Pharmaceuticals on renal drug safety evaluation study
• Global scientific expertise built into every NB product & service
• An overview of vaccine development & sub-types
• Thought Leadership Workshop hosted by NB: Emerging in vitro technologies for gene therapy applications
• In vitro models for chronic kidney disease (CKD)
• iPSC-derived Retinal Organoids: an alternative in vitro model for drug discovery
• Dr Kathryn Garner, Head of Kidney Development at NB
• How to reduce drug attrition during drug development?
• Why is an in vitro model of the glomerulus desperately needed?
• New Product Launched – aProximate™ Assay-Ready Plates for transporter studies
• How a glomerulus in vitro model can accelerate drug development
• Retinal Organoids for Drug Discovery
• Gene therapy vectors: Preclinical testing with retinal organoids
• Organ-on-a-chip: the next generation tool for drug development?
• iPSC derived retinal organoids: A promising tool for modelling retinitis pigmentosa
• Leading drug transport & drug toxicity expert, Dr Colin Brown joins NB
• iPSC-derived retinal organoids
• ESTIV 2018 International Congress
• Newcells head to Boston
• Looking forward: A year in review
• WHY WE DO IT
• HOW WE DO IT
• WHAT WE DO
• WHO WE ARE
• NB win Phase I of CRACK IT Challenge 29: ImmuLiver – securing £99,711 funding
• Newcells Biotech technology: the fight against antibacterial resistance
• NB completes a licensing agreement with iPS Academia Japan, Inc. for induced pluripotent stem cell technologies
• Dr Frank Armstrong appointed as Non-executive Director
• NB RPE model to improve drug retinal toxicity assessment
• Vision for the future of childhood retinal dystrophies
• Newcells Biotech acquires IP for retinal organoids
• NB hiPSC lung models; Valuable tools in understanding health impacts of air pollution
• NB win Phase II of CRACK IT Challenge 29: ImmuLiver
• Pulmonary toxicity – a challenge for drug development
• Covid-19 action plan – A message to our customers, collaboration partners & colleagues
• NB testing an in vitro model of the human lung epithelium for application in the fight against SARS-CoV-2
• The Human Cell Atlas – an aid to understanding COVID-19 & a valuable tool in the development of hiPSC models
• Biologics & the kidney – importance of transport & safety assessment

Pages

• Newcells @ ESGCT 2025
• Sitemap
• Advanced Retinal Models –
  Revolutionising Retinal Research
• Book a call
• Your meeting is booked
• Product Order Form
• Newcells @ ADDS 2025
• Newcells @ APT 2025
• Newcells @ ARVO 2025
• Newcells @ ASGCT 2025
• Contact – Service Enquiries
• Newcells @ Eurotox 2025
• Newcells @ MPS World Summit 2025
• Newcells @ TIDES USA 2025
• Newcells @ OTS 2025
• Service Selector
• Predictive In Vitro Models
• Projects Feedback Form
• Products Feedback Form
• The most advanced, freshly isolated in vitro kidney proximal tubule cell (PTC) model for nephrotoxicity assays
• Homepage
• Predictive In Vitro Models
  • Models of the Kidney Nephron
    • Proximal Tubule
    • Drug Transporter Interactions & DDI study
    • Cross Species Comparison Service
    • Kidney Toxicity Service
    • Kidney Disease Modelling Service
    • Assay-Ready Plates
    • Kidney Functional & Efficacy Study
  • Lung Airway Models
    • High-Throughout High-Sensitivity
      Lung FMT Assay
      
    • Human Lung Fibroblasts
    • Small Airway Epithelial Cell Model
    • Lung Toxicity Service
  • Retina Models
    • Retinal Organoids
    • Retinal Pigment Epithelium (RPE)
    • Gene Therapy Vector Assessment
    • Retinal Disease Modelling Service
    • Retinal Toxicity Service
    • Retina Efficacy Study
• Resources
• About
  • Events
  • Careers
  • Local Representatives
    • Asia & Australia
    • Europe
    • North America
    • Rest of World
  • Newcells Seminar Tour: Moving compounds to IND with predictive models
• Updates
• Terms of Use
• Contact
• Privacy Policy
• Small Airway Epithelial Cell Model
• Fibroblast-to-Myofibroblast Transition Assay
• Pipeline
• TERMS AND CONDITIONS FOR SALE OF PRODUCT & SERVICES
• State-of-the-Art Imaging Suite
  • Lung ciliary beat frequency analysis
• Lung Ciliary Beat Frequency Analysis
• Accelerate Your Drug Discovery
• Contact – Product Enquiries
• FAQs
• Applications

Resources

• Predictive in vitro Primary Proximal Tubule Models for Understanding Nephrotoxicity in Drug Development Programs
• Human Induced Pluripotent Stem Cell (hiPSC)-derived Retinal Model Containing Microglial Cells
• Reducing Compound Attrition by Predicting Renal Tubular Toxicity with in vitro PTEC Models
• A Human iPSC-derived Model of SARS-CoV-2 Infection & Pathogenesis in the Lung
• NIH/NEI 3D-ROC Sponsor Webinar
• Retinal Organoids as an Emerging Tool for Drug Discovery
• The Kidney as a Therapeutic Target: Targeting Therapeutics to the Proximal Tubule
• Retinal Organoids eBook
• Application of organoid technology for retinal disease modelling & drug discovery
• Lung Model Aids SARS-CoV-2 Research
• Development of a physiologically relevant lung model for understanding SARS-CoV-2 infection
• In vitro platforms for de-risking nephrotoxicity during drug development
• aProximate™ Assay-Ready Plates (Human, 24-well) User Guide
• Renal Proximal Tubule Cells Model eBook
• Improved in vitro renal tubular drug transport modelling to meet challenges
• The aProximate™ in vitro renal proximal tubule cell model as a platform to investigate the renal uptake and nephrotoxic liability of biologics
• An inter-species comparison of the triclopyr in vitro and in vivo toxicokinetic properties, for risk assessment purpose
• Development of predictive in vitro cross-species proximal tubule models for nephrotoxicity studies
• Development of a predictive in vitro human proximal tubule platform for de-risking nephrotoxicity
• Human primary proximal tubule cell monolayers as a novel predictive model of nephrotoxicity
• Characterization of cisplatin toxicity in aProximate™ human proximal tubule cell monolayers
• P52 – Determination of aminoglycoside toxicity in human renal proximal tubule monolayers using clinical relevant biomarkers of nephrotoxicity
• Complementary in vitro tools to investigate renal drug transport
• Primary human proximal tubule cell monolayers as a predictive model of renal phosphate homeostasis in heath & disease
• Developing High Content Imaging Assays for Chronic Kidney Disease
• JSAAE Poster Presentation
• Tropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids
• Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling
• Human-induced pluripotent stem cells generate light responsive retinal organoids with variable and nutrient-dependent efficiency
• Freshly isolated primary human proximal tubule cells as an in vitro model for the detection of renal tubular toxicity
• Room temperature shipment does not affect the biological activity of pluripotent stem cell derived retinal organoids
• Derivation of a system-independent Ki for p-glycoprotein mediated digoxin transport from system-dependent IC50 data
• In vitro models for accurate prediction of renal tubular xenobiotic transport in vivo
• Enhancing immune function of hiPSC-derived retinal organoids by incorporating microglial cells
• Human iPSC differentiation to retinal organoids in response to IGF1 and BMP4 activation is line- & method-dependent
• Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics
• Using statistical models to identify key variables critical for generation of retinal organoids from iPSC
• Differentiation of retinal organoids from human pluripotent stem cells
• aProximate™ as a novel, predictive model of aminoglycoside-induced nephrotoxicity
• Development of a novel predictive in vitro non human primate proximal tubule model for drug transporter & nephrotoxicity studies
• c-Rel orchestrates energy-dependent epithelial & macrophage reprogramming in fibrosis
• The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane
• The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression & function in the proximal tubule
• The importance of incorporating OCT2 plasma membrane expression and membrane potential in IVIVE of metformin renal secretory clearance
• Review of pharmacokinetics & metabolism of triclopyr herbicide in mammals: Impact on safety assessments
• In vitro selection of the most relevant species to predict human renal toxicity
• The chlorophenoxy herbicide MCPA: A mechanistic basis for the observed differences in toxicological profile in humans & rats vs dogs.
• Incorporating microglia-like cells in human induced pluripotent stem cell-derived retinal organoids
• aProximate™ Assay-Ready Plates (Human, 96-well) User Guide
• MPS World Summit 2022: in vitro model of podocyte damage
• Development of highly-differentiated human primary proximal tubule MPS model
• A solution for shipping primary human proximal tubule cell monolayers between laboratories
• The aProximate™ in vitro renal proximal tubule cell model as a platform to investigate the renal uptake & nephrotoxic liability of Antisense Oligonucleotide drug molecules
• Developing a Comprehensive Biomarker Package for Detecting Drug-Induced Injury in Podocytes
• Comprehensive in vitro evaluation of ocular toxicity and phenotypic rescue
• Retinal Organoids as a Tool for In Vitro Pre-clinical Testing – Newcells Biotech
• Quantitative Fibroblast-to-Myofibroblast Transition (FMT) studies
• Comparison of multiple batches of human iPSC-derived retinal organoids produced at large scale
• An in-vitro high-content imaging assay for the study of fibroblast activation and matrix deposition
• The aProximate™ in vitro renal proximal tubule cell model as a platform to investigate the renal uptake and nephrotoxic liability of Antisense Oligonucleotide drug molecules
• Development of highly-differentiated human primary proximal tubule MPS model (aProximate MPS™ Flow)
• Meet Dr Valeria Chichagova – Associate Director of iPSC Technology & Head of Retina
• Our Retinal Model Capabilities – Dr Valeria Chichagova
• A Live Cell High Content Imaging Assay for Monitoring Large Molecules Uptake into aProximateTM Proximal Tubule Epithelial Cells via Megalin and Cubulin
• Latest trends in Retinal Organoids: Scientific chat with Dr Valeria Chichagova
• The inside story of lung in vitro models with Dr Megan Webster
• Q&A with Dr Carolina Gandara, Head of retina assay development
• Meet Dr Megan Webster – Former Head Of Lung Development (2020-2024)
• A Sensitive Nephrotoxicity Assay of in vitro Podocyte Effacement
• Significance of OAT2 and OCT2 in creatinine clearance: Mechanistic evaluation using freshly-prepared human primary renal proximal tubule cells
• Overcoming technical difficulties of in vitro assay – development
• Development of a Highly Differentiated Human Primary Proximal Tubule MPS Model (aProximate MPS Flow)
• The inside story of the development of Newcells’ MPS flow model: Scientific chat with Dr Colin Brown
• A predictive in vitro primary proximal tubule platform for derisking of antibiotic-induced kidney injury
• About Newcells Biotech – Dr Mike Nicholds
• An in vitro Human Primary Thick Ascending Limb Model For The Assessment of Compound Nephrotoxicity
• A Primary Human in vitro Focal Segmental Glomerulosclerosis (FSGS) model for drug development applications
• Lung models eBook
• A high-throughput, in vitro assessment of antibiotic induced podocyte injury
• An in vitro model that predicts Antibiotic Renal Toxicity
• Modelling Epithelial Barrier Function and Mucociliary Clearance Using Small Airway Epithelium Cells
• Developing predictive in vitro Glomerulus , Proximal Tubule and Loop of Henle renal cell model platforms to investigate the renal uptake and nephrotoxic liability of large molecules
• Development of photoreceptor outer segments in human iPSC derived retinal organoids produced at large scale
• Evaluation of glomerular ADC toxicity in podocytes
• The aProximate^TM model for renal drug safety/efficacy and transporter studies
• Comparison of the Impact of VRP-034 and Polymyxin B upon markers of Kidney Injury in Human Proximal Tubule Monolayers In Vitro
• Newcells Biotech strengthens executive and US team with key appointments
• High content imaging (HCI) assays enable the study of the fibrotic processes: fibroblast – to – myofibroblast transition (FMT) and epithelial – to – mesenchymal transition (EMT)
• High throughput, high sensitivity (HTHS) lung fibroblast-to-myofibroblasts transition (FMT) assay for anti-fibrotic drug screening
• How Newcells Works With Clients – Dr Mike Nicholds
• The Newcells Biotech Offering – Dr Mike Nicholds
• Meet Dr Kathryn Garner – Former Head of Kidney Development (2021-2024)
• Our Kidney Model Capabilities – Newcells Biotech
• Utilization of high – content imaging for the study of lung fibrosis
• Small airway epithelial cell (SAEC) model
• The aProximateᵀᴹ Proximal tubule cells (PTC) model
• iPSC-derived Retinal Organoids (RO)
• iPSC-derived Retinal Pigment Epithelium (RPE)
• Ciliary beat frequency analysis assay for lung small airway epithelium cells (SAEC)
• Gene therapy viral vector assessment on retinal organoids
• Gene therapy viral vector assessment on RPE cells
• Meet the scientists: Anusha Gupta, the scientist behind the development of the CBF assay
• Meet the scientists: Dr Fiona Leslie, the scientist behind the development of the advanced FMT assay
• Our Lung Model Capabilities – Newcells Biotech
• Creating a Powerful NAM Respiratory Toxicology Strategy for Clinical Predictivity and IND Success
• Moving Compounds to IND Using Predictive Retina Models
• Predicting human renal injury from antisense oligonucleotide (ASO)
• Unravelling genotype-phenotype correlations in Stargardt disease using patient-derived retinal organoids
• Use of the aProximate Proximal Tubule Cell model for the evaluation of safety and renal accumulation of radioconjugates and large molecules
• Generation of a physiologically relevant in vitro model of autosomal dominant Retinitis Pigmentosa caused by RHO-P23H mutation using 3D retinal organoids
• The Real Impact of In Vitro Kidney Models: Better Data, Safer Drugs
• Comparing the transduction efficiency of two AAV vectors in RPE and Retinal Organoid models derived from iPSCs lines
• Safety and efficacy evaluation of a novel therapeutic AAV vectors using a human retinal organoid model
• Comprehensive toxicity study on retinal ganglion cells in early-stage human retinal organoids
• Development and characterisation of an early-stage retinal organoid disease model (for non-ocular disease)
• Analysis of the effect of a compound on retinal microtissue composition
• Development of a human in vitro model for retinitis pigmentosa
• Predicting renal retention of radioconjugates in a human relevant in vitro model
• Assessing the validity of a nephron model for a metabolic disease study
• DDI study on renal creatinine clearance mechanism
• Harnessing Advanced In Vitro Lung Assays for Compound Screening
• In Vitro Retinal Models: A New Era in Drug Discovery & Gene Therapy
• Making safety decisions for a sunscreen active ingredient using next-generation risk assessment: Benzophenone-4 case study
• Utilizing rat kidney gene co-expression networks to enhance safety assessment biomarker identification and human translation

Events

• Webinar: The Real Impact of In Vitro Kidney Models: Better Data, Safer Drugs
• SOT 64th Annual Meeting and ToxExpo
• 4th Ace Drug Discovery Summit
• Cell & Gene Meeting on the Mediterranean
• ARVO Annual Meeting
• 28th ASGCT Annual Meeting
• TIDES USA
• 4th Microphysiological Systems World Summit
• 59th EUROTOX Congress
• ESGCT Congress
• 21st Annual Oligonucleotide Therapeutics Society Meeting
• LinkedIn Live: In Vitro Retinal Models: A New Era in Drug Discovery & Gene Therapy
• LinkedIn Live: Advancing Radioconjugate Therapeutics: Leveraging Kidney PTC Models for Predictive Uptake and Toxicity Assessment

Our People

• Dr Colin Brown
• Richard Strike
• Dr Valeria Chichagova
• Simon Berry
• Prof Lyle Armstrong
• Dr Mike Nicholds
• Terry Pizzie
• Victoria Wiesener
• Alan Williams
• Rhys Powell
• Amy Mawdesley
• Dr Mark Carnegie-Brown